Focused On-demand Library for RNA-binding protein 8A

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9Y5S9

UPID:

RBM8A_HUMAN

Alternative names:

Binder of OVCA1-1; RNA-binding motif protein 8A; RNA-binding protein Y14; Ribonucleoprotein RBM8A

Alternative UPACC:

Q9Y5S9; B3KQI9; Q6FHD1; Q6IQ40; Q9GZX8; Q9NZI4

Background:

RNA-binding protein 8A, also known as RNA-binding motif protein 8A, RNA-binding protein Y14, and Ribonucleoprotein RBM8A, plays a crucial role in pre-mRNA splicing as part of the spliceosome. It is a core component of the exon junction complex (EJC), marking the position of exon-exon junctions in mature mRNA, thereby influencing mRNA metabolism, including export, localization, translation efficiency, and decay.

Therapeutic significance:

The involvement of RNA-binding protein 8A in Thrombocytopenia-absent radius syndrome, a disorder characterized by skeletal anomalies and thrombocytopenia, underscores its potential as a target for therapeutic intervention. Understanding the role of RNA-binding protein 8A could open doors to potential therapeutic strategies.